KRAS and neoplasm: Additionally, we demonstrate that this method, when combined with syngeneic mouse tumor models, provides valuable insights into the guanine-nucleotide binding state of KRAS in tumor tissues and serves as an effective tool for evaluating the efficacy of KRAS/G12C inhibitors in vivo.